28-Mar-2024
No headlines found.
Globe Newswire (Wed, 6-Mar 7:30 AM ET)
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 1-Mar 5:00 PM ET)
Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
Globe Newswire (Tue, 27-Feb 4:01 PM ET)
Globe Newswire (Mon, 26-Feb 7:30 AM ET)
Kura Oncology to Participate in Three Upcoming Investor Conferences
Globe Newswire (Thu, 22-Feb 7:30 AM ET)
Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results
Globe Newswire (Tue, 20-Feb 7:30 AM ET)
Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia
Globe Newswire (Tue, 30-Jan 7:00 AM ET)
Kura Oncology Announces Oversubscribed $150 Million Private Placement
Globe Newswire (Wed, 24-Jan 7:00 AM ET)
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.
Kura Oncology trades on the NASDAQ stock market under the symbol KURA.
As of March 28, 2024, KURA stock price climbed to $21.33 with 819,448 million shares trading.
KURA has a beta of 0.88, meaning it tends to be less sensitive to market movements. KURA has a correlation of 0.03 to the broad based SPY ETF.
KURA has a market cap of $1.62 billion. This is considered a Small Cap stock.
Last quarter Kura Oncology reported $0 in Revenue and -$.55 earnings per share. This met revenue expectation and met earnings estimates .
In the last 3 years, KURA stock traded as high as $30.37 and as low as $7.41.
The top ETF exchange traded funds that KURA belongs to (by Net Assets): XBI, VTI, IWM, VXF, IWN.
KURA has outperformed the market in the last year with a return of +77.3%, while the SPY ETF gained +33.6%. In the last 3 month period, KURA beat the market returning +50.0%, while SPY returned +10.1%. However, in the most recent 2 weeks KURA has underperformed the stock market by returning -6.6%, while SPY returned +1.7%.
KURA support price is $20.42 and resistance is $21.92 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KURA stock will trade within this expected range on the day.